NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$88.24
+19.26 (+27.92%)
Close of Nov 06, 2026 · end-of-day data
TMDX 8-K filings in 2025
Every material Form 8-K TransMedics Group filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TransMedics reported third quarter 2025 revenue of $143.8 million, up 32% from $108.8 million a year earlier, and net income of $24.3 million, or $0.66 per diluted share, compared with $4.2 million, or $0.12 per diluted share, in the third quarter of 2024. The company raised the midpoint of its full year 2025 revenue guidance and narrowed the range to $595 million to $605 million, which shareholders will weigh against the prior range of $585 million to $605 million.
Q3 2025 total revenue of $143.8 million, up 32% from $108.8 million in Q3 2024
Q3 2025 net income of $24.3 million, or $0.66 per diluted share, versus $4.2 million, or $0.12, a year earlier
Full year 2025 revenue guidance narrowed to $595 million to $605 million, from $585 million to $605 million given on July 30, 2025
Gross margin was 59% in Q3 2025, compared with 56% in Q3 2024; cash was $466.2 million as of September 30, 2025
TransMedics, Inc., a wholly-owned subsidiary of TransMedics Group, Inc., bought one fixed-wing aircraft from Teaghlach Aviation, LLC on October 3, 2025, for approximately $14.5 million. The company says it now has 22 aircraft in total and plans to use them to transport donor organs under its National OCS Program. The filing describes this as an incremental addition to a fleet built through earlier acquisitions.
Purchase date: October 3, 2025, from Teaghlach Aviation, LLC
Purchase price: approximately $14.5 million
Total aircraft acquired to date: 22 (21 in prior acquisitions plus this one)
Stated use: transporting donor organs as part of the National OCS Program
TransMedics reported second-quarter 2025 revenue of $157.4 million, up 38% from $114.3 million a year earlier, and net income of $34.9 million, or $0.92 per diluted share, versus $12.2 million in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $585 million to $605 million from the prior range of $565 million to $585 million, which is the main development for shareholders.
Q2 2025 total revenue was $157.4 million, up 38% from $114.3 million in Q2 2024
Q2 2025 net income was $34.9 million, or $0.92 per diluted share, compared with $12.2 million, or $0.35 per diluted share, a year earlier
Full-year 2025 revenue guidance raised to $585 million to $605 million from $565 million to $585 million
Gross margin was 61%, consistent with the prior-year quarter; operating expenses rose to $60.0 million from $56.8 million
TransMedics reported first quarter 2025 revenue of $143.5 million, up 48% from $96.9 million a year earlier, and net income of $25.7 million, or $0.70 per diluted share, versus $12.2 million in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $565 million to $585 million from the previous $530 million to $552 million range, which both headline measures and the outlook point to stronger results for shareholders.
Q1 2025 total revenue was $143.5 million, a 48% increase from $96.9 million in Q1 2024.
Net income was $25.7 million, or $0.70 per fully diluted share, compared with $12.2 million, or $0.35 per diluted share, a year earlier.
Full-year 2025 revenue guidance was raised to $565 million to $585 million from $530 million to $552 million, as reported February 27, 2025; gross margin was 61% versus 62% a year earlier.
TransMedics reported fourth-quarter and full-year 2024 results on February 27, 2025, with revenue of $121.6 million for the quarter, up 50%, and $441.5 million for the year, up 83%. The company posted full-year net income of $35.5 million, or $1.01 per diluted share, compared with a net loss of $25.0 million in 2023, and expects 2025 revenue of $530 million to $552 million.
Q4 2024 revenue of $121.6 million, up 50% from $81.2 million; Q4 net income of $6.9 million, or $0.19 per diluted share
Full-year 2024 gross margin of 59.4%, down from 63.8% in 2023; operating expenses of $224.6 million
2025 revenue outlook of $530 million to $552 million, representing 20% to 25% growth
On February 20, 2025, TransMedics, Inc., a wholly-owned subsidiary of TransMedics Group, Inc., bought one fixed-wing aircraft from Ocean Select Seafood, L.L.C. for approximately $14.3 million. The filing says the company intends to use all 21 aircraft it has acquired to date to transport donor organs under its National OCS Program, and it treats the purchases as a series of related transactions. The filing reports no revenue, profit, or guidance figures, so its effect on shareholders is limited to the added spending and fleet.
Aircraft purchased February 20, 2025, from Ocean Select Seafood, L.L.C. for approximately $14.3 million
Brings the total to 21 aircraft acquired to date, including 20 in prior acquisitions reported in 13 earlier 8-K filings
Aircraft are intended for transporting donor organs as part of the National OCS Program
TransMedics Group said its subsidiary bought a fixed-wing aircraft from RCS Leasing, LLC on January 8, 2025, for approximately $14.1 million. The company says it now holds 20 aircraft acquired to date, which it uses to transport donor organs under its National OCS Program.
Purchase on January 8, 2025 from RCS Leasing, LLC for approximately $14.1 million
Buyer is TransMedics, Inc., a wholly-owned subsidiary of the company
Total of 20 aircraft acquired to date, including 19 in prior acquisitions
Aircraft are used to transport donor organs as part of the National OCS Program
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TransMedics Group filing is on SEC EDGAR ↗. 8-K briefs of other companies →